AZIN1 and cancer: Although, RNA therapeutics targeting cancer-driven or associated RNA editing events have not yet been identified or introduced into the clinic, AZIN1 may serve as a therapeutic target for anticancer drug development superior to polyamine synthesis inhibitors and warrants further studies.